Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 9 of 205 for:    MIRASOL

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04209855
Recruitment Status : Recruiting
First Posted : December 24, 2019
Last Update Posted : January 10, 2022
Gynecologic Oncology Group
European Network of Gynaecological Oncological Trial Groupbs
Information provided by (Responsible Party):
ImmunoGen, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : September 2023